



14 June 2022

For Immediate Release

AUSTRALIAN BLOODSTREAM INFECTION TEST CLEARED FOR SALE IN EUROPE

Australian biotech scaleup, Microbio is set to break into the European market with its flagship bloodstream infection (BSI) test.

Following extensive clinical evaluation trials, the company has been granted a CE Mark, which has opened the door for distribution and use in Europe.

CEO Paul Carboon said Microbio's InfectID-BSI test has the potential to significantly advance the detection of bloodstream infection and sepsis, the world's biggest killer.

"We are excited to receive the CE Mark for our InfectID-BSI test which moves us a step closer to providing this powerful diagnostic tool to clinicians across the globe," Mr Carboon said.

"Europe is an important market for us and now that we have completed internationally recognised clinical trials, we expect new markets to come online as appropriate approvals are achieved."

Microbio is now seeking accreditation for its InfectID-BSI test in Australia, USA, India and other jurisdictions.

Bloodstream infections and sepsis result in 11 million deaths annually, killing more people than all forms of cancer.

Dr Ron Daniels BEM, Founder and Joint CEO of UK Sepsis Trust and the Global Sepsis Alliance Vice President says that Microbio's InfectID-BSI is likely to change the way we diagnose and treat patients with bloodstream infections and sepsis due to two key properties which make it stand out.

"The fact that the test operates directly from whole blood and provides results in a clinically relevant time period (less than three hours) across a broad pathogen target range means that we can now look to use InfectID-BSI in the clinical setting, offsetting the requirement to await formal Blood Culture results, helping to target immediate prescription of appropriate antibiotics," Dr Daniels said.

Dr Raffaella Giardino, International In Vitro Diagnostic industry expert said that the most important concern in sepsis is quick diagnosis and prompt treatment.

"With InfectID-BSI, for the first time a test will be able to deliver a rapid answer directly from blood, better sensitivity and specificity than the current method and uses standard equipment available in every clinical laboratory," Dr Giardino said.

The current 'gold standard' method to identify the causative pathogen is a slow, two-step blood culturing and identification process that takes between 12 hours and several days and has limited sensitivity.

Microbio's InfectID-BSI is an in vitro diagnostic test which significantly improves patient outcomes by alerting clinicians within three hours of taking a blood sample which infection to treat.

Based in Queensland's Translational Research Institute, Microbio said the launch of the InfectID-BSI test was keenly anticipated and marks a major milestone for the company and a breakthrough in rapid detection of bloodstream infections and sepsis.

Microbio's InfectID-BSI test provides the potential for early bloodstream infection and sepsis diagnosis, and therefore earlier use of optimal antimicrobials which is likely to reduce the length of hospital stays and healthcare costs.

The diagnostic test identifies 26 common BSI/sepsis-causing pathogens, using Real-Time Polymerase Chain Reaction (RT-PCR) instruments, which are open hardware platforms used in pathology labs around the world.

For more information, visit <https://microbio.com.au/>.

-ENDS-

About Microbio

Microbio is an Australian scale-up biotechnology company based in Brisbane. The team at Microbio has brought together the latest advances in bioinformatics, genomics and molecular microbiology to develop a unique and revolutionary pathogen detection test. The Microbio team is working tirelessly to deliver their game-changing new test to the millions of patients who will benefit from better pathogen diagnosis. Microbio is actively seeking partners worldwide, especially in population health and virology, who will integrate this new information into their proactive regional and corporate testing protocols. Additionally, Microbio is looking to work with pathology laboratory partners who can help deliver these highly specific results faster and to remote locations to improve health, regardless of a patient's location.

About InfectID

InfectID is a diagnostic technology that detects and identifies bacterial, fungal, and viral targets. The test targets the pathogen's DNA 'fingerprint', found at a specific point in each pathogen's genetic code. By focusing on the genetic fingerprint rather than the whole genome, the process is fast, inexpensive, highly sensitive and can be adapted to target different pathogens. The technology was refined and became the foundation of Microbio's flagship product: InfectID-Bloodstream Infection. InfectID-BSI uses real-time Polymerase Chain Reaction (qPCR) to identify sepsis-causing pathogen species directly from blood without the need for pre-culture.

Microbio Founders

Paul Carboon | Executive Director, Founder and Chief Executive Officer

Paul has 30 years of commercialisation experience in the technology sector. Paul brings deep understanding of commercial and product management as well as product development and been an executive for over 10 years. Paul has PMBOK in Project Management, GAICD, and has completed CEO Master Class and is a leader in biotechnology innovation. He currently serves on the AusMedtech national advisory group and is a member of the Australian Medtech Manufacturing Centre Advisory Group. Paul is also an Honorary Fellow of Biotechnology at Melbourne University.

Dr Flavia Huygens | Executive Director, Founder and Chief Scientific Officer

Flavia's 30-year teaching and research career has focused on molecular microbiology, with a particular focus on human pathogens. Flavia's expertise and exceptional ability to bring together emerging technology in molecular microbiology, genomics, proteomics and bioinformatics have culminated in the creation of InfectID.